| SIGNALOMICS GMBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20110237451 | COMPETITIVE N-HYBRID SYSTEM - A method of identifying high-affinity ligands, comprising the following steps:
| 09-29-2011 |
| 20110110856 | Optimized Adhesin Fragments And Corresponding Nanoparticles - The invention relates to optimized adhesins and nanoparticles to which said adhesins are bound. The invention furthermore relates to providing said nanoparticles by way of in vivo contrast agents, in particular for the diagnosis of bowel cancer. | 05-12-2011 |
| 20100297772 | METHOD FOR THE CREATION OF GENETIC DIVERSITY IN VIVO - Disclosed is a method for creating genetic diversity in vivo, comprising the following steps: fragments of at least one wild-type gene sequence are produced, each of said fragments being provided with at least one region which is homologous with a vector that is suitable for in vivo recombination; randomized bridging oligonucleotides of at least one defined oligonucleotide sequence are produced, parts of the bridging oligonucleotide being homologous with at least one fragment of the wild-type gene sequence; and the linearized vector, at least one wild-type fragment, and the randomized bridging oligonucleotide/s are introduced into an in vivo system for homologous recombination. | 11-25-2010 |
| 20090239935 | RNA-HELICASE AS A MARKER FOR RARE TUMORS - Method for the diagnosis of diseases in a mammal, preferably in a human, wherein a probe from the mammal is examined with a view to an elevated level of RNA helicase and the elevated level of RNA helicase indicates the disease. The disease refers to esophagus carcinoma, pancreas carcinoma, stomach carcinoma, hepatocellular carcinoma, hepatoblastoma and cholangiocellular carcinoma. | 09-24-2009 |
| 20090163370 | Competitive N-Hybrid System - The invention relates to a method for identifying highly affinous ligands comprising the following steps: a) creating a bank for a mutagenized first hybrid protein comprising a plurality of mutants; b) expression of a first hybrid protein in a host with a second hybrid protein, one of the hybrid proteins comprising the DNA binding domain of a transcription factor and a bait protein and the other hybrid protein comprising the activation domain for a transcription factor and a prey protein; c) allowing the binding reaction between the first and second hybrid protein in order to form a complex with a functional transcription factor in the host cell under reaction conditions, which are such that the balance of the binding reaction is offset on the side of the hybrid proteins; d) detecting the binding reaction by detecting a reporter gene expressed via the functional transcription factor; e) optionally repeating one or more steps from a) to d); f) selection of a mutant. | 06-25-2009 |
